



# Proteomics International

LABORATORIES LTD

ASX Release  
28 January 2021

ASX code: PIQ

## Issue of Options

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) advises that further to the ASX announcement of 23 October 2020 and following receipt of shareholder approval at the extraordinary general meeting held earlier today, a total of 2,200,000 options (**Options**) have been issued to nominees of Euroz Hartleys Securities Limited and Candour Advisory Pty Ltd.

Euroz Hartleys acted as Sole Lead Manager and Bookrunner to the placement, and Candour Advisory acted as Corporate Advisor to the placement which raised \$6 million from UK and Australian-based institutions, and sophisticated and professional investors.

The Options have an exercise price of \$0.75 per option and an expiry date of 28 January 2023.

An Appendix 3B will be lodged separately.

### Secondary Trading Notice Pursuant to Paragraph 708A(5)(e) of the Corporations Act 2001 ("Act")

The Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under section 708 or 708A of the Act. By giving this notice, a sale of the Options noted above will fall within the exemption in section 708A(5) of the Act.

The Company hereby notifies ASX under paragraph 708A(5)(e) of the Act that:

- (a) the Company issued the Options without disclosure to investors under Part 6D.2 of the Act;
- (b) as at the date of this Notice, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and section 674 of the Act; and
- (c) as at the date of this Notice, there is no information:
  - i. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
  - ii. that investors and their professional advisers would reasonably require for the purposes of making an informed assessment of:
    - a. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
    - b. the rights and liabilities attaching to the relevant Options.

Authorised by the Board Proteomics International Laboratories Ltd (ASX:PIQ).

ENDS

### For further information please contact:

Dr Richard Lipscombe  
Managing Director  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Dirk van Dissel  
Corporate Advisor & Investor Relations  
T: +61 408 326 367  
E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

Kyle Moss  
Corporate Advisor  
Euroz Hartleys Securities  
T: +61 9488 1400

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)